Researchers at Sutter’s California Pacific Medical Center (CPMC) in San Francisco, Calif. have discovered early signs of clinical benefit while testing niraparib, a PARP inhibitor, in patients with advanced melanoma whose tumors had specific genetic changes impacting DNA repair.

Scientists and medics have developed an ultra-rapid method of genetically diagnosing brain tumours that will cut the time it takes to classify them from 6-8 weeks, to as little as two hours – which could improve care for thousands of patients each year in the UK.

The groundbreaking method, which is detailed in a new study published today in Neuro-Oncology, has been developed by scientists at the University of Nottingham along with clinicians at Nottingham University Hospitals NHS Trust (NUH).

In the published work, the team at NUH utilised the new approach during 50 brain tumour surgeries to deliver rapid, intraoperative diagnoses. This approach has achieved a 100% success rate, providing diagnostic results in under two hours from surgery and detailed tumour classifications within minutes of sequencing. Moreover, the platform’s ability to continue sequencing enables a fully integrated diagnosis within 24 hours.